Cyr61 Expression is associated with prognosis in patients with colorectal cancer

Dongjun Jeong1,6, Suhak Heo2, Tae Sung Ahn3, Sookyong Lee1, Soyoung Park1, Hyungjoo Kim1, Doosan Park1, Sang Byung Bae4, Sung Soo Lee5, Moon Soo Lee3, Chang-Jin Kim1 and Moo Jun Baek3*

Abstract

Background: Cysteine-rich 61 (Cyr61), a member of the CCN protein family, possesses diverse functionality in cellular processes such as adhesion, migration, proliferation, and survival. Cyr61 can also function as an oncogene or a tumour suppressor, depending on the origin of the cancer. Only a few studies have reported Cyr61 expression in colorectal cancer. In this study, we assessed the Cyr61 expression in 251 colorectal cancers with clinical follow up.

Methods: We examined Cyr61 expression in 6 colorectal cancer cell lines (HT29, Colo205, Lovo, HCT116, SW480, SW620) and 20 sets of paired normal and colorectal cancer tissues by western blot. To validate the association of Cyr61 expression with clinicopathological parameters, we assessed Cyr61 expression using tissue microarray analysis of primary colorectal cancer by immunohistochemical analysis.

Results: We verified that all of the cancer cell lines expressed Cyr61; 2 cell lines (HT29 and Colo205) demonstrated Cyr61 expression to a slight extent, while 4 cell lines (Lovo, HCT116, SW480, SW620) demonstrated greater Cyr61 expression than HT29 and Colo205 cell lines. Among the 20 cases of paired normal and tumour tissues, greater Cyr61 expression was observed in 16 (80%) tumour tissues than in normal tissues. Furthermore, 157 out of 251 cases (62.5%) of colorectal cancer examined in this study displayed strong Cyr61 expression. Cyr61 expression was found to be associated with pN (p = 0.018). Moreover, Cyr61 expression was associated with statistically significant cancer-specific mortality (p = 0.029). The duration of survival was significantly lesser in patients with Cyr61 high expression than in patients with Cyr61 low expression (p = 0.001). These results suggest that Cyr61 expression plays several important roles in carcinogenesis and may also be a good prognostic marker for colorectal cancer.

Conclusions: Our data confirmed that Cyr61 was expressed in colorectal cancers and the expression was correlated with worse prognosis of colorectal cancers.

Keywords: Colorectal cancer, Cyr61, Immunohistochemistry, Prognosis

Background

Cysteine-rich 61 (Cyr61) is a member of the CCN (Cyr61/CTGF/Nov) protein family, which consists of Cyr61 (CCN1); connective tissue growth factor (CTGF/CCN2), nephroblastoma-overexpressed (Nov/CCN3); and Wnt-induced secreted proteins 1, 2 and 3 (Wisp-1/CCN4, Wisp-2/CCN5, and Wisp-3/CCN6, respectively). These CCN proteins are involved in multiple functional pathways, including mitogenesis, cellular adhesion, migration, cell survival, differentiation, angiogenesis, and wound healing [1]. Among the various CCN proteins, a majority of studies have been conducted on Cyr61 or CCN1 with reference to cancer. Cyr61 is expressed by all types of vascular cells, participating in such diverse cellular processes as adhesion, migration, proliferation, and survival [2,3]. Notably, an important role for Cyr61 in the processes of angiogenesis and vascularization is being seen. Neovascularization of tumours is one of the most important functions of tumour growth factors; thus, Cyr61 participates in tumour progression by neovascularization. In addition to angiogenesis, CCN1 can promote cancer cell proliferation, invasion, survival, and metastasis [4,5]. Overexpression of Cyr61 is associated with the growth and progression of breast cancer [6], ovarian cancer [7], gastric cancer [8,9],

* Correspondence: ssurge@schmc.ac.kr
 Department of Surgery, College of Medicine, Soonchunhyang University, 31 soonchunhyang 6 gil, Dongnam-gu, Cheonan, Chungcheongnam-do 330-722, Republic of Korea
 Full list of author information is available at the end of the article
and glioma [10,11]. In contrast, Cyr61 has also been shown to function as a tumour suppressor in prostate cancer [12], uterine leiomyoma [13], non-small cell lung cancer [14,15], and endometrial cancer [16]. Cyr61 may exert different, even opposing, functions in tumorigenesis, depending on the cell types.

Colorectal cancer (CRC) is one of the commonest cancers worldwide and was ranked second in 2010 for cancer incidence in South Korea [17]. At least 3 primary molecular pathways involved in the progression of CRC have been identified, including the prevalent chromosomal instability (CIN) pathway (identified in up to 80% of cases), the CpG island methylator phenotype (CIMP) pathway, and microsatellite instability (MSI), resulting from the DNA mismatch repair (MMR) gene [18]. However, the precise mechanism underlying colorectal carcinogenesis remains unclear.

More recently, studies have focused primarily on molecular biomarkers to indicate progression of a disease or susceptibility of the disease to a given treatment [19].

Cyr61 plays important roles in carcinogenesis, either as an oncogene or as a tumour suppressor gene, depending on the cancer type. The purpose of our study is to clarify whether Cyr61 functions as an oncogene or as an anti-oncogene in CRC and to determine whether there is a correlation between Cyr61 expression and clinicopathological parameters, including prognosis. We also verified that Cyr61 is a relevant biomarker of CRC progression.

**Methods**

**Patients and samples**

We obtained formalin-fixed, paraffin-embedded specimens from 251 patients with primary CRC. All patients with cancer underwent surgery from 2002 to 2007. Clinicopathological data including age, sex, lymph node metastasis, American Joint Committee on Cancer (AJCC) TNM classification, and tumour differentiation were recorded (Table 1). Our work was approved by the Institutional Review Board of the College of Medicine, Soonchunhyang University.

**Western blot assay**

Cancer cells were washed with PBS and lysed using the Pro-Prep protein extraction kit (Intron, Seoul, South Korea) at 4°C overnight. The supernatant containing protein was collected after centrifugation. Protein concentrations were determined using a BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). Cell lysate samples (30 μg) were loaded onto 10% SDS-PAGE, separated at 110 V for 2 h, and transferred to a PVDF membrane with the Trans-Blot Turbo system (Bio-Rad Laboratories, Hercules, CA, USA). The membrane was blocked for 1 h in blocking buffer consisting of 5% non-fat skim milk/1X TBS-T (Tris-buffered saline with 0.1% Tween 20) for 1 h at room temperature, followed by incubation with primary monoclonal anti-Cyr61 antibody at 4°C overnight, diluted in 1X TBS-T (1:1000; R&D Systems, Minneapolis, MN, USA). After a 5 times wash with TBS-T, the membrane was incubated with a goat anti-mouse secondary antibody in 1X TBS-T (1:80,000 dilution; Sigma Chemicals, St. Louis, MO, USA) for 1 h at room temperature. The membranes were washed 4–5 times in 1X TBS-T for 1 h. The signal was detected using an enhanced chemiluminescence kit (ECM solution; Advansta, Menlo Park, CA, USA) and Molecular Imager ChemiDoc XRS + System (Bio-Rad Laboratories). Beta-actin was used as the loading control. The relative Cyr61 expression was measured by Image Densitometer (Bio-Rad, Laboratories) with beta-actin normalization. The relative Cyr61 expressions in tumour tissues compared to those in normal tissues were calculated by tumour/normal ratio.

**Tissue microarray**

Tissue microarrays (TMAs) were assembled from 10% neutral buffered formalin-fixed paraffin-embedded tissues by using a 2-mm-diameter punch (UNITMA, Unitech Science, Seoul, South Korea). Tissue microarrays were constructed by obtaining primarily duplicate cores of formalin-fixed

---

**Table 1 Clinicopathological factors of the study**

| Clinicopathological factors | Number |
|----------------------------|--------|
| Sex                        |        |
| Male                       | 147    |
| Female                     | 104    |
| pT stage                   |        |
| 1                          | 10     |
| 2                          | 41     |
| 3                          | 171    |
| 4                          | 29     |
| pN stage                   |        |
| 0                          | 136    |
| 1                          | 75     |
| 2                          | 40     |
| Vascular invasion          |        |
| 0                          | 219    |
| 1                          | 32     |
| Lymphatic invasion         |        |
| 0                          | 212    |
| 1                          | 39     |
| TNM stage                  |        |
| I                          | 35     |
| II                         | 98     |
| III                        | 105    |
| IV                         | 13     |
paraffin-embedded tumour specimens and re-embedding the cores in an arrayed recipient paraffin block. A TMA block contains 60 cores from 30 samples. Samples obtained from the same tumour were staggered in the array, and a map was created for later identification of the identity of the individual cores.

**Immunohistochemical analysis**

Four-micrometer-thick sections were sliced onto Silane Coated Micro Slides (Muto Pure Chemicals Corp., Tokyo, Japan) and incubated at 60°C for 2 h. The slides were then deparaffinized by application of xylene and incubation (5 min × 3) at room temperature. Sections were hydrated by application of graded alcohol, and endogenous peroxidase activity was quenched by incubating the sections in 0.3% H2O2 in methanol for 30 min at room temperature. After washing the slides in phosphate-buffered saline (PBS; 5 min × 2), antigen retrieval was performed by heating the slides in citrate buffer (0.01M, pH 6.0) using a microwave in a pressure cooker for 15 min. After heating, the samples were allowed to cool off for 2 h at room temperature followed by washing with PBS (3 min × 2). Immunohistochemical (IHC) analysis was performed using Cyto61 primary antibody (Abcam, Cambridge, UK) with incubation for 2 h at room temperature with an UltraVision Quanto Detection System HRP DAB (Lab Vision Corp., Fremont, CA, USA) according to the manufacturer’s instructions.

**IHC data analysis**

The Cyto61-stained tissue cores were examined by 2 independent observers (CJK and DJJ), and a consensus score was determined for each specimen. A positive reaction was scored into 4 grades, according to the intensity of the staining: 0, 1+, 2+, and 3+. The percentages of Cyto61-positive cells were also scored into 4 categories: 0 (0%), 1 (1–33%), 2 (34–66%), and 3 (67–100%). The final score, calculated as the product of the intensity score multiplied by the percentage score, was classified as follows: 0 for negative; 1–3 for weak; 4–6 for moderate; and 7–9 for strong. Samples with a final score ≤3 were grouped together as Cyto61 expression negative while those with a score ≥4 were grouped together as Cyto61 expression positive.

**Statistical analysis**

The data were analysed using commercially available software (SPSS 18.0; SPSS; Chicago, IL, USA). The clinical and pathologic factors that were evaluated included pT (1, 2, 3, and 4), pN (0, 1, and 2), vascular invasion, lymphatic invasion, and TNM stage classification (I, II, III, and IV). For investigating the relationships between Cyto61 expression and the clinicopathological factors, chi-square tests were performed. A p value, two-sided test was also performed; values less than 0.05 were considered statistically significant for all analyses. The clinical and pathologic variables and Cyto61 expression were considered for survival analysis using the Kaplan-Meier method. The statistical significance was set at a p value less than 0.05 and assessed by the log-rank test. Hazard ratio (HR) and 95% confidence interval (95% CI) were estimated from Cox proportional hazard models. For final multivariable Cox regression models, all covariates were controlled.

**Results**

Cyto61 protein expression in CRC cell lines and normal-cancer paired CRC tissues by western blot

We examined Cyto61 expression in 6 CRC cell lines by Western blot. All 6 cancer cell lines expressed Cyto61; 2 cell lines (HT29 and Colo205) demonstrated slight Cyto61 expression, while 4 cell lines (Lovo, HCT116, SW480, SW620) demonstrated greater Cyto61 expression than the HT29 and Colo205 cell lines (Figure 1A). Furthermore, we examined Cyto61 expression in 20 sets of paired normal and CRC tissues by western blot. Among the 20 normal and tumour tissue pairs, greater Cyto61 expression was observed in tumour tissues versus normal tissues in 16 cases (80%) (Figure 1B).

Cyto61 expression in CRC tissue by Immunohistochemistry

Cyto61 was not expressed in most normal tissues. In tumour tissue, Cyto61 was expressed with a wide range of intensity, ranging from negative to severe staining (Figure 2A-D). Among the 251 cases, a positive result for IHC Cyto61 staining was observed in 157 samples (62.2%) (Table 2). The frequency of Cyto61 expression was 5.1%, 12.7%, 66.9%, and 15.3% for pT stages 1, 2, 3, and 4, respectively. Positive Cyto61 expression was significantly related with the pT stage (p = 0.021). The frequencies of Cyto61 expression for pN stages 0, 1, and 2 were 46.5%, 35.7% and 17.8%, respectively; these results were statistically significant (p = 0.006). Furthermore, the frequencies of Cyto61 expression were 13.4% and 16.6% when examining vascular invasion and lymphatic invasion, respectively; however, these results were not statistically significant (p = 0.700 and p = 0.563, respectively). However, the frequencies of Cyto61 expression for TNM stages I, II, III, and IV were 10.8%, 32.5%, 50.3%, and 6.4% respectively (p = 0.001); the results were statistically significant (Table 2). Age, sex, pT stage, venous invasion, lymphatic invasion, tumour differentiation were not related with prognosis by univariate and multivariate Cox hazard regression analysis. pN stage 1 was found to be associated with prognosis in multivariate analysis (HR, 2.02; 95% CI, 1.04–3.94; p = 0.038). Additionally, pN stage 2 was associated with prognosis both in univariate analysis (HR, 2.90; 95% CI, 1.44–5.83; p = 0.003) and in multivariate analysis (HR, 2.53; 95% CI, 1.20–5.32; p = 0.015) (Table 3). Moreover, strong Cyto61 expression was found to be prognostic factor both in univariate analysis (HR, 2.56; 95% CI, 1.29–5.08; p = 0.007).
and in multivariate analysis (HR, 2.31; 95% CI, 1.09–4.89; p = 0.029), as determined by Cox hazard regression analysis (Table 3). The duration of survival was significantly lesser in patients with Cyr61 high expression than in those Cyr61 low expression (p = 0.001) (Figure 3).

**Discussion**

Cyr61 is a multifunctional matricellular protein that performs various essential roles in cardiovascular development during embryogenesis, as well as regulates wound healing, inflammation, and fibrogenesis [20]. Aberrant Cyr61 expression is associated with the development of various cancers and diseases linked to chronic inflammation. Cyr61 promotes diverse, and sometimes opposing, cellular responses. Structurally, CYR61 protein consists of an N-terminal secretory peptide followed by 4 conserved domains with sequence homologies to insulin-like growth factor-binding protein (IGFBP), von Willebrand factor C repeat (VWC), thrombospondin type I repeat (TSR), and a carboxyl-terminal (CT) domain that contains a cysteine knot motif [1]. A nonconserved central hinge region bisects the protein into 2 halves that bind to distinct receptors and induce diverse and disparate cellular responses. Early studies on Cyr61 protein showed that it is tightly associated with the extracellular matrix (ECM) [21] and supports cellular adhesion by direct binding to integrin receptors [22,23]. Cyr61 functions as a matricellular protein rather than a growth factor to induce cell proliferation.

---

**Figure 1** Western blot analysis of Cyr61 expression. (A) All of the cancer cell lines expressed Cyr61. (B) Representative 10 pairs of normal and tumour tissue. Greater Cyr61 expressions were observed in tumour tissues than in normal tissues. The relative Cyr61 expression was measured by densitometry with beta-actin normalization (*). The relative Cyr61 expressions in tumour tissues compared to those in normal tissues were calculated by tumour/normal ratio (T/N).

**Figure 2** Cyr61 expressions in tissues by immunohistochemistry. (A) Normal glands in the colorectum demonstrate negative Cyr61 expression. (B) Some colorectal cancer shows negative Cyr61 expression. (C) Cyr61 is expressed in mild degree in the carcinoma. (D) Cyr61 is expressed in severe degree in the carcinoma.
Cyr61 also demonstrates various disparate cellular activities; for example, it promotes cellular survival, yet triggers cellular apoptosis; it enhances cell proliferation, yet induces cell-cycle arrest; and it promotes tumour growth, yet suppresses tumorigenesis in varying contexts, depending on the cell type. These disparate Cyr61 activities are attributed to its interaction with distinct integrins and heparan sulphate proteoglycans (HSPGs) on the surface of both endothelial cells and stromal fibroblasts. These Cyr61 activities stimulate both epithelial-mesenchymal transition and invasion of certain cancer cells [4,5,25]. Moreover, Cyr61 induces angiogenesis, which is essential for the supply of oxygen and nutrients to nourish tumour growth [26]. In addition to angiogenesis, Cyr61 promotes cancer cell proliferation, invasion, survival, and metastasis [4,5,27]. Significant correlation between Cyr61 expression and tumour stage, tumour size, lymph node positivity, and poor prognosis have been reported in several types of cancers, including breast cancer [3,28-31], prostate cancer [32], glioma [33], gastric cancer [9], and oral squamous cell carcinoma [34]. However, only a few studies have been performed on the relationship between Cyr61 expression and CRC initiation and/or progression. A single report by Ladwa et al. [35] was retrieved in a worldwide search of journals published in English; they reported that Cyr61 was expressed in 82% (23/28) of CRCs examined and that Cyr61 expression was associated with more advanced clinical stages. In our study, all 7 CRC cell lines expressed Cyr61 with varying intensities. Five cell lines exhibited relatively strong expression levels of Cyr61, while 2 cell lines expressed lower levels of Cyr61. Furthermore, among the 20 sets of paired normal and cancer tissues, the tumour tissues exhibited stronger Cyr61 expression than paired normal tissues in 16 cases (80%). This result suggests that Cyr61 plays several roles in colorectal carcinogenesis, a hypothesis supported by the Cyr61 expression levels observed by IHC analysis in clinical samples. Among 251 cases of CRCs examined in this study, 157 cases (62.5%) displayed strong Cyr61 expression. The prevalence of Cyr61 expression in our study is lower than that reported by Landwa et al. [35]. This discrepancy could be attributed to either sample size or different primary antibodies used in the

| Table 2 Comparison of clinicopathological factors and Cyr61 expression |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| **Clinicopathological factors** | **Cyr61** | **Total (%)** | **p** |
| | **Positive N = 157 (%)** | **Negative N = 94 (%)** | |
| Age, years, mean (SD) | 62.2 (12.2) | 65.2 (11.5) | 63.3 (12.0) | 0.061 |
| Sex | | | | 0.296 |
| Male | 88 (56.1) | 59 (62.8) | 147 (58.6) | |
| Female | 69 (43.9) | 35 (37.2) | 104 (41.4) | |
| pT stage | | | | 0.021 |
| 1 | 8 (5.1) | 2 (2.1) | 10 (4.0) | |
| 2 | 20 (12.7) | 21 (22.3) | 41 (16.3) | |
| 3 | 105 (66.9) | 66 (70.2) | 171 (68.1) | |
| 4 | 24 (15.3) | 5 (5.3) | 29 (11.6) | |
| pN stage | | | | 0.006 |
| 0 | 73 (46.5) | 63 (67.0) | 136 (54.2) | |
| 1 | 56 (35.7) | 19 (20.2) | 75 (29.9) | |
| 2 | 28 (17.8) | 12 (12.8) | 40 (15.9) | |
| Vascular invasion | | | | 0.700 |
| 0 | 136 (86.6) | 83 (88.3) | 219 (87.3) | |
| 1 | 21 (13.4) | 11 (11.7) | 32 (12.7) | |
| Lymphatic invasion | | | | 0.563 |
| 0 | 131 (83.4) | 81 (86.2) | 212 (84.5) | |
| 1 | 26 (16.6) | 13 (13.8) | 39 (15.5) | |
| TNM stage | | | | 0.001 |
| I | 17 (10.8) | 18 (19.1) | 35 (13.9) | |
| II | 51 (32.5) | 47 (50.0) | 98 (39.0) | |
| III | 79 (50.3) | 26 (27.7) | 105 (41.8) | |
| IV | 10 (6.4) | 3 (3.2) | 13 (5.2) | |

Jeong et al. BMC Cancer 2014, 14:164
http://www.biomedcentral.com/1471-2407/14/164
### Table 3 Cox hazards regression analysis of the clinicopathological factors

| Clinicopathological factors | Univariate analysis | P       | Multivariate analysis | P     |
|-----------------------------|---------------------|---------|-----------------------|-------|
|                             | Hazard ratio (95% CI) |         | Hazard ratio (95% CI) |       |
| Age                         | 1.01 (0.99–1.03)     | 0.514   | 1.00 (0.98–1.03)      | 0.858 |
| Sex (0 = male, 1 = female)  | 1.03 (0.60–1.77)     | 0.917   | 1.20 (0.66–2.20)      | 0.548 |
| pT stage                    |                     |         |                       |       |
| 1                           | 1.00                |         | 1.00                  |       |
| 2                           | 1.09 (0.24–5.03)     | 0.916   | 0.93 (0.18–4.86)      | 0.927 |
| 3                           | 1.13 (0.27–4.70)     | 0.864   | 0.99 (0.19–4.88)      | 0.967 |
| 4                           | 3.44 (0.68–17.78)    | 0.140   | 2.15 (0.34–13.86)     | 0.419 |
| pN stage                    |                     |         |                       |       |
| 0                           | 1.00                |         | 1.00                  |       |
| 1                           | 1.83 (0.99–3.40)     | 0.056   | 2.02 (1.04–3.94)      | 0.038 |
| 2                           | 2.90 (1.44–5.83)     | 0.003   | 2.53 (1.20–5.32)      | 0.015 |
| Venous invasion             | 1.00 (0.45–2.21)     | 0.991   | 0.67 (0.23–1.96)      | 0.463 |
| Lymphatic invasion          | 1.84 (0.98–3.44)     | 0.057   | 1.97 (0.79–4.90)      | 0.143 |
| Differentiation             |                     |         |                       |       |
| Well                        | 1.00                |         | 1.00                  |       |
| Moderate                    | 0.70 (0.36–1.40)     | 0.298   | 0.61 (0.28–1.30)      | 0.198 |
| Poor                        | 0.86 (0.24–3.08)     | 0.817   | 0.75 (0.18–3.09)      | 0.692 |
| Cyr61 Expression            |                     |         |                       |       |
| Negative                    | 1.00                |         | 1.00                  |       |
| Negative to mild expression | 0.89 (0.48–1.67)     | 0.721   | 0.86 (0.44–1.70)      | 0.662 |
| Moderate to severe expression| 2.56 (1.29–5.08)    | 0.007   | 2.31 (1.09–4.89)      | 0.029 |

CI, confidence interval.

**Figure 3** Survival curves from the time of diagnosis for colorectal cancer patients by Cyr61 expression. The duration of survival was significantly lesser in patients with Cyr61 high expression than in those with Cyr61 low expression.
IHC analysis. Moreover, Cyr61 expression played some role in the progression of CRC in this study, as Cyr61 expression levels were higher in more advanced pT, pN, and TNM stages than in less advanced stages. Strong Cyr61 expression was associated with poor prognosis (p = 0.029), as determined by Cox hazard regression analysis. The survival analysis, performed using the Kaplan-Meier method, demonstrated that survival was significantly lower in patients with Cyr61 high expression than in patients with Cyr61 low expression (log rank test, p = 0.002). This study reports the first survival analysis involving the IHC evaluation of Cyr61 expression in CRC. The results of this study support the hypothesis that Cyr61 promotes cancer cell proliferation, invasion, and metastasis [4,5,26,27]. However, several lines of evidence support the hypothesis that Cyr61 can suppress tumour growth functioning as an antioncogene. Cyr61 inhibits NSCLC cell proliferation by upregulating p53, p21, and p130/Rb gene expression [15], suggesting that Cyr61 may induce senescence through a p53-/pRb-dependent pathway [36]. Likewise, overexpression of Cyr61 inhibits the proliferation of hepatocellular carcinoma cells, in part through p53 action [37]. Furthermore, overexpression of Cyr61 in endometrial carcinoma cells has been reported to decrease cell growth and increase apoptosis [16]. Additionally, Cyr61 expression in melanoma cells reduces tumour growth and metastasis and concomitantly increases apoptosis in tumours [38]. Thus, the role of Cyr61 in tumorigenesis may be dependent on cell type and context. In conclusion, the results of this study suggest that Cyr61 expression plays an important role in the carcinogenesis and progression of CRC, as well as in predicting patient survival. Further investigations may validate the potential utility of Cyr61 as a biomarker or therapeutic target against CRC.

Conclusions

Our data suggest that Cyr61 expression in colorectal cancers is associated with patients survival and may thus serve as prognostic marker.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

DJ, CK, MSL, SL and MIB designed and supervised the study; DJ, CJK, MSL, SL, MIB, SP, HK, DP, HIK, YWJ, TSA, SLL and SHH acquired data and interpreted results; DJ, CK, and MIB wrote the manuscript, but all authors helped with the drafting and editing. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by the Soonchunhyang University Research Fund.

Author details

1. Department of Pathology, College of Medicine, Soonchunhyang University, 31 soonchunhyang 6gil, Dongnam-gu, Cheonan, Chungcheongnam-do 330-722, Republic of Korea. 2. Department of Oncology, College of Medicine, Soonchunhyang University, 31 soonchunhyang 6gil, Dongnam-gu, Cheonan, Chungcheongnam-do 330-722, Republic of Korea. 3. Department of Preventive Medicine, College of Medicine, Soonchunhyang University, 31 soonchunhyang 6gil, Dongnam-gu, Cheonan, Chungcheongnam-do 330-722, Republic of Korea.

Received: 25 March 2013 Accepted: 28 February 2014

Published: 7 March 2014

References

1. Holbourn KP, Acharya RR, Perbal B: The CCN family of proteins: structure-function relationships. Trends BiochemSci 2008, 33:461–473.
2. Holloway SE, Beck AW, Girard L, Jabber MR, Babert CC, Breitken RA, Fleming JB: Increased expression of Cyr61 (CCN1) identified in pentitoneal metastases from human pancreatic cancer. J Am Coll Surg 2005, 200:371–377.
3. Xie D, Miller CW, O’Kelly J, Nakachi K, Sakashita A, Said JW, Gombein J, Koeffler HP: Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 2001, 276:14187–14194.
4. Sun ZJ, Wang Y, Cai Z, Chen PP, Tong XJ, Xie D: Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells. Br J Cancer 2008, 99:1656–1667.
5. Kasis JS, Virador VM, Guancial EA, Kimm D, Ho AS, Mishra M, Chuang EY, Cook J, Gius D, Kohn EC: Genetic and phenotypic analysis reveals a key role for CCN1 (Cyr61) in BAG3-modulated adhesion and invasion. J Pathol 2009, 218:495–504.
6. Tsa MS, Bojarg OF, Castaneda JM, Li P, Lupu R: Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 2002, 21:8178–8185.
7. Gery S, Xie D, Yin D, Gabara H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW, Koeffler HP: Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 2005, 11:7243–7254.
8. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF: Cyr61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998, 95:6355–6360.
9. Lin MT, Zuan CY, Chang CC, Chen ST, Chen CP, Lin BR, Wang MY, Jeng YM, Chang KI, Lee PH, Chen WJ, Kuo ML: Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res 2005, 11:3809–3820.
10. Xie D, Yim D, Wang HJ, Liu GT, Elashoff R, Black K, Koeffler HP: Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004, 10:2072–2081.
11. Xie D, Yim D, Tong X, O’Kelly J, Mori A, Miller C, Black K, Gui D, Said JW, Koeffler HP: Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/LEF signaling pathways. Cancer Res 2004, 64:1987–1996.
12. Pllanes CP, Schmitd U, Eissrich C, Stade J, Froschermaier SE, Haase M, Faller G, Kirchner TW, Wittk MP: Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998, 36:85–91.
13. Sampath D, Zhu Y, Winneker RC, Zhang Z: Aberrant expression of Cyr61, a member of the CCN (Cytgf/Cyr61/Cef10/NOVH) family, and dysregulation by 17 beta-estradiol and basic fibroblast growth factor in human uterine leiomyomas. J Clin Endocrinol Metab 2001, 86:1707–1715.
14. Tong X, Xie D, O’Kelly J, Miller CW, Muller-Tidow C, Koeffler HP: Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J Biol Chem 2001, 276:47709–47714.
15. Tong X, O’Kelly J, Xie D, Mori A, Lemp N, McKenna R, Miller CW, Koeffler HP: Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway. Oncogene 2004, 23:4847–4855.
16. Chang KJ, Lee PH, Chen WJ, Kuo ML: Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res 2005, 11:3809–3820.
17. Lin MT, Zuan CY, Chang CC, Chen ST, Chen CP, Lin BR, Wang MY, Jeng YM, Chang KI, Lee PH, Chen WJ, Kuo ML: Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res 2005, 11:3809–3820.
18. Pllanes CP, Schmidt U, Eissrich C, Stade J, Froschermaier SE, Haase M, Faller G, Kirchner TW, Wittk MP: Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998, 36:85–91.
19. Sampath D, Zhu Y, Winneker RC, Zhang Z: Aberrant expression of Cyr61, a member of the CCN (Cytgf/Cyr61/Cef10/NOVH) family, and dysregulation by 17 beta-estradiol and basic fibroblast growth factor in human uterine leiomyomas. J Clin Endocrinol Metab 2001, 86:1707–1715.
20. Tong X, Xie D, O’Kelly J, Miller CW, Muller-Tidow C, Koeffler HP: Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J Biol Chem 2001, 276:47709–47714.
21. Tong X, O’Kelly J, Xie D, Mori A, Lemp N, McKenna R, Miller CW, Koeffler HP: Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway. Oncogene 2004, 23:4847–4855.
Cite this article as: Jeong et al. Cyr61 Expression is associated with prognosis in patients with colorectal cancer. BMC Cancer 2014 14:164.